ClinicalTrials.gg
RecruitingNCT04837352FELSA-SEPUpdated Mar 26, 2024

Therapeutic Adherence of Multiple Sclerosis Patients

An observational study in Multiple Sclerosis, sponsored by Lille Catholic University. Recruiting at 4 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-26.

Sponsored by Lille Catholic University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2022; still recruiting 4 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
153
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Multiple Sclerosis by Lille Catholic University — 5 open to participants now, 5 under way, none of them phase 3. Multiple Sclerosis · Lille Catholic University.

Started
2022
with 1 other
Observational
7 of 18
1 open now
Registered
12th of 18
by date

Among the 18 studies in Multiple Sclerosis by Lille Catholic University, this one is one of 2 that started in 2022, is one of 7 observational ones, and was the 12th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

5 of the 18 studies in Multiple Sclerosis by Lille Catholic University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Multiple Sclerosis by Lille Catholic University, or all of them as a file.
02

Study summary

The goal of this study is to assess the role of sociocognitive and interpersonal factors in the therapeutic adherence of multiple sclerosis patients. This study will provide a better understanding of the socio-psychological issues associated with different types of non-adherence to treatment, and identify the risk factors and vulnerability of each patient.

Read the detailed description

Multiple sclerosis is a chronic and progressive disease that affects young adults (between 20 and 40 years old), impacting significantly the patients quality of life.

The adherence to therapy affects the long-term functional clinical course (lower risk of relapses, reduction in disability progression and quality of life). The non-adherence rate to therapy in multiple sclerosis is estimated at 40%. The main identified causes of non-adherence are: forgetting to take treatment and adverse effects of drugs.

Sociocognitive models as the Theory of Planned Behaviour (TPB) have been developed to help to understand and predict health-related behaviours. This model postulates that the intention to adopt a behaviour is one of the major determinants in the context of health. This intention comes from three independent elements :

  • Personal positive or negative attitudes towards the behaviour,
  • Social expectations or entourage perception (subjective norms),
  • Difficulty in accomplishing this behaviour (perceived control)

Multiple sclerosis adherence to therapy studies have mainly focused on somatic variables (physical disability, illness duration, type of treatment) and some clinical variables (cognitive impairment, fatigue, depression). The few studies that have examined the multiple sclerosis therapeutic adherence determinants have mainly taken a one-dimensional perspective, such as perceived control.

In the FELSA-SEP study, the role of sociocognitive factors (norms and beliefs, perceived threat to disease and health behaviours) and interpersonal factors (social support, patient-doctor relationship) will be explored.

03

Conditions studied

  • Multiple Sclerosis

Keywords

  • Theory of Planned Behaviour
  • Therapeutic adherence
  • Sociocognitive and interpersonal factors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Persons with multiple sclerosis who will be recruited during a routine neurological consultation and who present eligibility criterion.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Multiple sclerosis defined according to McDonald criteria;
  • Already undergone or beginning substantive treatment (self-managed, excluding treatment administered in hospital)
  • Aged ≥ 18 years;
  • Given the form.

Exclusion criteria

Exclusion Criteria:

  • Severe cognitive impairment (score below the 5th percentile);
  • Any associated neurological pathology or serious or chronic somatic disease (cancer);
  • Being under a legal protection measure.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
153 participants (estimated)
Patient registry
No

Groups and cohorts

  • Multiple sclerosis patients

    Patients with multiple sclerosis over 18 years old who have already started a long-term treatment and consent to participate to the study

    Other: Study of the role of sociocognitive factors

Interventions

  • OtherStudy of the role of sociocognitive factors

    Questionnaires

06

What researchers measure

Primary outcomes

  1. Therapeutic adherence evaluated by a Likert scale

    This 19-item self-questionnaire provides 5 sub-scores corresponding to each of the sub-dimensions (Attitudes, Subjective norms, Perception of control, Behavioural intention and Behaviour) and an overall score (sum of the 5 sub-scores).

    Time frame: 6 months

Secondary outcomes

  1. Perceived threat measured with a self-assessment form

    The perceived threat will be measured with a self-assessment form using a 5-point scale ranging from 1 (strongly disagree) to 5 (strongly agree). This 11-item self-questionnaire provides 2 sub-scores and an overall score (sum of the 2 sub-scores).

    Time frame: 3 weeks

  2. Perceived interpersonal relationships quality measure by the perceived social support questionnaire (QSSP)

    * The QSSP is a 6 items questionnaire which assess availability and satisfaction with respect to perceived social support. * 4-Point ordinal Alliance Scale (11-items 4-PAS). This self-questionnaire concerns the patient's perception about the therapeutic alliance.

    Time frame: 6 months

  3. Perceived interpersonal relationships quality measure by the 4-Point ordinal Alliance Scale (11-items 4-PAS)

    The 4-Point ordinal Alliance Scale (11-items 4-PAS). This self-questionnaire concerns the patient's feelings about the therapeutic alliance and includes eleven items, placing the patient on 5-point scale on : the patient's feeling about the doctor's ability to help him/her; his/her understanding of the symptoms of the illness; the psychological improvement felt; the adaptation to the doctor-patient relationship; the doctor's availability and competence; the clarity of the information given by the doctor and the understanding he/she shows; the doctor's desire of clinical improvement; the quality of the relationship and the understanding of psychological difficulties

    Time frame: 6 months

  4. Illness duration in days

    In order to evaluate the vulnerability and protective factors related to somatic disease illness duration will be evaluated.

    Time frame: 3 weeks

  5. Handicap will be evaluated by the Expanded Disability Status Scale (EDSS)

    In order to evaluate the vulnerability and protective factors related to somatic the handicap will be evaluated by the EDSS. The EDSS quantifies disability in eight Functional Systems (FS) by assigning a Functional System Score in each of these functional systems. The clinical meaning of each possible result goes from 0.0: Normal Neurological Exam to 10.0: Death

    Time frame: 3 weeks

  6. Relapses number

    In order to evaluate the vulnerability and protective factors related to somatic disease number of relapses will be evaluated

    Time frame: 3 weeks

  7. Fatigue perceived through the FSS (Fatigue Severity Scale)

    In order to evaluate the vulnerability and protective factors related to somatic disease fatigue will be evaluated. The items are scored on a 7 point scale with 1 = strongly disagree and 7= strongly agree. The minimum score = 9 and maximum score possible = 63. Higher the score = greater fatigue severity.

    Time frame: 3 weeks

  8. Cognitive disorders through the SDMT (Symbol Digit Modalities Test)

    In order to evaluate the vulnerability and protective factors related to somatic disease cognitive disorders will be evaluated The SDMT is a sign coding test that assesses attentional abilities (sustained attention and speed of processing information). Participants are required to use a coded key to match nine abstract symbols paired with numerical digits. The final score is the correct number of substitutions in 90 seconds, and scores range between 0 and 110.

    Time frame: 3 weeks

  9. Anxiety-depressive symptoms measured by the Hospital Anxiety and Depression Scale (HADS)

    The vulnerability and protective factors linked to psychological functioning- as Anxiety-depressive symptoms will be determined. - Personality traits: Big Five Inventory-FR questionnaire (BFI-FR)

    Time frame: 3 weeks

  10. Personality traits measured by the Big Five Inventory-FR questionnaire (BFI-FR)

    The vulnerability and protective factors linked to psychological functioning as personality traits will be determined. The Big Five personality traits is a suggested grouping for personality traits. The theory identifies five factors: * openness to experience (inventive/curious vs. consistent/cautious) * conscientiousness (efficient/organized vs. extravagant/careless) * extraversion (outgoing/energetic vs. solitary/reserved) * agreeableness (friendly/compassionate vs. challenging/callous) * neuroticism (sensitive/nervous vs. resilient/confident)

    Time frame: 3 weeks

07

Study locations

4 of 4 sites recruiting
  • CHRU DE Bordeaux
    Bordeaux, France
    Recruiting
    • Florian HONTARREDE · Contact
    • Aurélie RUET · Principal investigator
  • Hôpital Saint-Vincent de Paul
    Lille, 59000, France
    Recruiting
    • Axelle DEBROUX · Contact
    • Bruno LENNE, PhD · Principal investigator
  • Hôpital Saint-Philibert
    Lomme, 59462, France
    Recruiting
    • Caroline MASSOT, MD · Contact
    • Caroline MASSOT, MD · Principal investigator
  • CHRU de Strasbourg
    Strasbourg, France
    Recruiting
    • Carole BERTHE · Contact
    • Thomas SENGER · Contact
    • Jérôme DE SEZE, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Jan 2025, 36 months after the start.

Of 336 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 81. This study's planned 36 months is close to that.

Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2021
First posted
Apr 8, 2021
StartActual
Jan 18, 2022
Primary completionEst.
Jan 18, 2025
CompletionEst.
Oct 18, 2025
Last update
Mar 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04837352
Responsible party
Sponsor
First posted
Apr 8, 2021
Start date
Jan 18, 2022
Primary completion
Jan 18, 2025 (estimated)
Completion
Oct 18, 2025 (estimated)
Last update
Mar 26, 2024

Study contacts

Marie-Paule Lebitasy, MD, PhD
Contact
Lebitasy.Marie-Paule@ghicl.net
03.20.22.52.69
Lucile POISSON, PhD
Contact
poisson.lucile@ghicl.net
03.20.22.59.02
Bruno Lenne
principal investigator · Hôpital Saint Vincent de Paul, Lille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion